Answers are grounded in this paper and cite their sources.
Case report demonstrates rituximab achieves biochemical normalization in overlap syndrome, suggesting a viable option for treatment.
Abstract Autoimmune hepatitis (AIH) and primary biliary cholangitis (PBC) may coexist as an overlap syndrome, which can be challenging to diagnose and manage. In this case report, we describe a patient with AIH–PBC overlap syndrome refractory to conventional immunosuppressive therapy and with steroid-dependent disease. Rituximab was administered as rescue therapy, achieving biochemical normalization. This case supports the potential role of rituximab as a therapeutic option in patients refractory to standard immunosuppressive treatments.
No takes yet. Share an insight, caveat, or question.
Martinez et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: